Papers

1

Total Citations

3

H-Index

1

About

Keri Callegari is a researcher whose work sits at the intersection of drug discovery and neurodegenerative disease biology. Her primary research focus involves developing innovative screening methodologies to identify potential therapeutic compounds for protein misfolding disorders, including Alzheimer's and Parkinson's disease. Her most cited work, "Development of a Fluorescent Quenching Based High Throughput Assay to Screen for Calcineurin Inhibitors" (2015), represents a significant methodological contribution to the field. This assay provides a scalable, efficient platform for identifying calcineurin inhibitors, an enzyme pathway implicated in neurodegeneration and other disease states. While her citation count is still growing, Callegari's work addresses a critical gap: the current lack of effective treatments for major neurodegenerative disorders. By creating tools that enable rapid, high-throughput screening, she is helping to accelerate the drug discovery pipeline. Her research is particularly valuable for students and researchers interested in assay development, protein misfolding, and the translational path from basic science to therapeutic intervention.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Development of a Fluorescent Quenching Based High Throughput Assay to Screen for Calcineurin Inhibitors
3 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: The University of Texas Health Science Center at Houston

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago